Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. IBM
5. META
6. SPY
7. ACN
8. NVDA
9. PRIM
10. PFE

Go back to Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
(NASDAQ: EWTX) Delayed: 39.17 +2.67 (7.32%)
Previous Close $36.50    52 Week High $ 
Open $36.31    52 Week Low $ 
Day High $39.30    P/E N/A 
Day Low $36.30    EPS $ 
Volume 394,053